How long should an ipamorelin cycle be?

Standard Cycle Structure

The canonical ipamorelin protocol:

• On-phase: 12 weeks at therapeutic dose
• Off-phase: 4 weeks no peptide
• Repeat indefinitely if desired

This produces roughly 9 months of active dosing per year with 3 months off, distributed across the year.

Why Cycle Rather Than Continuous

Receptor sensitivity

• Continuous stimulation can desensitize GHRP receptors over time
• Off periods allow receptors to return to baseline sensitivity
• Next cycle produces stronger response

Natural recovery windows

• Body's own GH axis maintains function better with cyclic use
• Prevents full dependency on exogenous stimulation

Assess baseline

• Off periods reveal true post-cycle status
• Helps evaluate whether continued use is worth it
• Clear before-vs-after comparison

Cost savings

• 4 weeks off per 16 weeks = 25% cost reduction annually
• At $250/month, saves $750/year

Cycle Length Variations

Short cycle (8 weeks)

• 8 weeks on, 2 weeks off
• Good for initial trial to assess response
• Minimizes side effect accumulation
• Slightly less cost per "year of coverage"

Standard cycle (12 weeks)

• 12 weeks on, 4 weeks off
• Most common in clinical practice
• Allows full expression of anti-aging and body composition effects
• Sustainable long-term pattern

Extended cycle (16 weeks)

• 16 weeks on, 4–6 weeks off
• For users with clear continued benefit
• Some receptor desensitization may start appearing

Continuous (not recommended)

• Indefinite daily dosing without breaks
• May lose effectiveness over 6+ months
• Higher long-term safety uncertainty
• Hard to evaluate actual benefit

When to Start a New Cycle

After complete off period

• Minimum 4 weeks off before restart
• Body should feel "back to baseline"
• Previous cycle benefits may partially fade (evidence of effect)

If benefits clearly persisting

• Consider extending off period
• Some users find 2–3 months off still retains gains
• Longer off periods = lower annual cost

If benefits faded quickly

• May indicate receptor sensitivity is a factor
• Consider shorter cycles going forward
• Or reconsider whether drug is adding value

Signs Your Current Cycle Is Done

• Benefits peaked weeks 4–8, now plateauing
• No further improvement in markers (IGF-1, body composition, sleep)
• Side effects becoming more prominent or persistent
• You're ready for an honest baseline check

What to Do During Off Periods

Continue training and nutrition fundamentals

• Resistance training maintained
• Protein intake kept up
• Sleep and stress management continued

Assess baseline

• Honest evaluation of what changes hold vs fade
• Note sleep quality changes
• Body composition assessment

Optional: natural GH support

• Sleep optimization remains high-leverage
• Fasted training can briefly spike GH
• Amino acids (arginine, glutamine) modest effect
• Avoid alcohol which suppresses GH

Multiple Cycles Per Year

Reasonable annual patterns:

• Conservative: 2 × 12-week cycles with 12-week gaps (6 months on, 6 months off)
• Moderate: 3 × 12-week cycles with 4-week gaps (9 months on, 3 months off)
• Aggressive: 4 × 8-week cycles with 4-week gaps (8 months on, 4 months off)

The moderate pattern is most common.

Long-Term Use (Years)

Clinical experience suggests:

• Cyclical use for 5+ years appears well-tolerated
• No known significant long-term safety signals
• Benefits may modestly diminish over years even with cycling
• Periodic full breaks (several months) help reset

Dose Changes Across Cycles

First cycle (weeks 1–12)

• Start at 100–200 mcg to assess tolerance
• Titrate up to 200–300 mcg 2–3× daily
• Evaluate response

Subsequent cycles

• Start at established effective dose
• Don't need to re-titrate unless taking long break
• Dose creep isn't usually needed

Combining Cycles With Other Peptides

Many users stack ipamorelin with CJC-1295 or BPC-157:

• Stacks typically follow same cycle length as ipamorelin
• Some BPC-157 users dose more continuously (different risk profile)
• CJC-1295 often cycled alongside ipamorelin

When to End Ipamorelin Use Permanently

• No longer seeing benefit after 2–3 cycles with good adherence
• Side effects becoming significant or persistent
• New medical conditions creating contraindications
• Life priorities no longer align with the expense
• Replaced by other interventions that address underlying needs

Returning After Long Break

If you've been off ipamorelin for months or years:

• Re-titrate from low starting dose
• Expect first 2 weeks may feel like first-time use
• Full cycle response may need 2–4 weeks to develop
• Labs at baseline useful (IGF-1, glucose) for comparison

Monitoring During Long-Term Use

Every 6 months

• IGF-1 levels
• Fasting glucose and HbA1c
• Basic metabolic panel

Every 12 months

• Full thyroid panel
• CBC
• Age-appropriate cancer screenings current

Bottom Line

Standard ipamorelin cycling is 12 weeks on, 4 weeks off. Avoid indefinite continuous dosing due to receptor desensitization and cost. Most users find 2–3 cycles per year works well. Maintain training and nutrition fundamentals during off periods. Clinical experience supports safe long-term cyclical use over years.

See the ipamorelin guide. Related: side effects, cost per month.